Infinity Pharmaceuticals, Inc. Overview
Pro stress-test →Infinity Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing immuno-oncology treatments for cancer. The company's lead candidate, eganelisib (IPI-549), is a first-in-class PI3K-gamma inhibitor being evaluated in multiple Phase 1/1b and Phase 2 clinical trials across solid tumors, triple negative breast cancer, and urothelial cancer. However, the company entered Chapter 11 bankruptcy liquidation in September 2023 with the liquidation plan approved in March 2024, significantly altering its operational status.
Strategic Profile
Pro stress-test →Prior to bankruptcy, Infinity pursued a collaboration-driven strategy with major pharmaceutical partners including Roche/Genentech, Bristol Myers Squibb, and other biotech companies to advance eganelisib combinations across multiple cancer indications. The company's competitive advantage centered on its novel mechanism targeting myeloid cell reprogramming within the tumor microenvironment, positioning it as a potential best-in-class immuno-oncology therapy when combined with checkpoint inhibitors.
Competitive Landscape
Pro stress-test →Infinity competed in the immuno-oncology space against established players like Bristol Myers Squibb (Opdivo), Merck (Keytruda), Roche (Tecentriq), and other PI3K inhibitor developers. Its differentiated approach targeting myeloid cells rather than T-cells offered potential advantage, but smaller scale and limited cash runway created competitive vulnerability against larger pharma competitors with diversified pipelines.
Industry Context
Infinity Pharmaceuticals, Inc. operates in Immuno-Oncology / Biopharmaceuticals.
Key facts
Founded: 1995 · Headquarters: Cambridge, Massachusetts · Employees: N/A · Revenue: N/A · Market cap: N/A